Stryker Corporation

Valuation Analysis

About the Company

Stryker Corporation en bref

Stryker Corporation (SYK) is currently trading at 268,48 € with a market capitalization of 102,9 Md €. The trailing P/E ratio stands at 35.69x, with a forward P/E of 18.42x. The 52-week range spans from 244,97 € to 352,95 €; the current price is 23.9% below the yearly high. Year-over-year revenue growth stands at +2.6%. The net profit margin stands at 13.21%.

💰 Dividende

Stryker Corporation pays an annual dividend of 3,07 € per share, representing a yield of 1.14%. The payout ratio stands at 39.81%.

📊 Avis des analystes

25 analystes évaluent Stryker Corporation (SYK) au consensus : Acheter. L'objectif de cours moyen est de 337,20 €, soit un potentiel de +25.6% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 274,61 € à 405,37 €.

Stryker Corporation : la thèse d'investissement en détail

Stryker Corporation (SYK) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 64.7%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Buy with an average price target implying roughly 25.6% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue growth has slowed to just 2.6%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The PEG ratio at 1.48 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

À surveiller

• The forward P/E of 18.42x is meaningfully below the trailing 35.69x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 25.6% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Stryker Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.